Russell Investments Group Ltd. Has $2.76 Million Stake in LivaNova PLC $LIVN

Key Points

• Russell Investments Group Ltd. significantly increased its stake in LivaNova PLC by 4,581.9%, acquiring 68,820 shares during the first quarter and bringing its total holdings to approximately 70,322 shares valued at $2.76 million.
• Analysts have raised their price targets for LivaNova, with Barclays and other firms adjusting their targets upward, reflecting a generally positive sentiment with multiple upgrades to 'strong-buy' and 'outperform' categories.
• LivaNova reported better-than-expected quarterly earnings, with an EPS of $1.05, surpassing analyst estimates and demonstrating a year-over-year revenue growth of 10.6%, reaching $352.5 million.

Russell Investments Group Ltd. lifted its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 4,581.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,322 shares of the company's stock after purchasing an additional 68,820 shares during the quarter. Russell Investments Group Ltd. owned 0.13% of LivaNova worth $2,762,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of LIVN. UMB Bank n.a. raised its position in shares of LivaNova by 340.5% during the first quarter. UMB Bank n.a. now owns 837 shares of the company's stock worth $33,000 after purchasing an additional 647 shares during the period. CWM LLC grew its holdings in shares of LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company's stock worth $34,000 after buying an additional 299 shares in the last quarter. Central Pacific Bank Trust Division grew its holdings in shares of LivaNova by 7.0% during the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock worth $173,000 after buying an additional 290 shares in the last quarter. Corton Capital Inc. bought a new position in shares of LivaNova during the fourth quarter worth about $214,000. Finally, Bayesian Capital Management LP bought a new position in shares of LivaNova during the fourth quarter worth about $218,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on LIVN. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a report on Tuesday, May 20th. Robert W. Baird increased their price objective on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Barclays increased their price objective on LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Wall Street Zen upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $64.00 price objective on shares of LivaNova in a report on Tuesday, May 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $59.71.

LivaNova Stock Down 1.8%

LIVN stock traded down $1.04 during mid-day trading on Thursday, reaching $55.45. The company had a trading volume of 445,519 shares, compared to its average volume of 706,575. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. The stock has a 50 day simple moving average of $47.11 and a two-hundred day simple moving average of $43.24. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of -14.25 and a beta of 0.92. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $57.35.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.84 by $0.21. The firm had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The business's revenue was up 10.6% compared to the same quarter last year. During the same period last year, the company earned $0.93 earnings per share. As a group, equities analysts predict that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.